Table 2 Baseline characteristics in participants with new atrial fibrillation diagnosed by continuous ECG monitoring and no atrial fibrillation
Atrial fibrillation | |||
|---|---|---|---|
Variable | New (n = 33) | Never (n = 413) | P-value |
Height (cm) median (IQR) | 174 (166–180) | 170 (163–178) | 0.040 |
Weight (kg) median (IQR) | 74 (70–86) | 73 (63.5–82.2) | 0.182 |
BMI, median (IQR) | 24.9 (22.6–27.1) | 24.9 (22.8–27.0) | 0.863 |
Systolic BP (mmHg) median (IQR) | 132 (124–151) | 138 (128–150) | 0.364 |
Diastolic BP (mmHg) median (IQR) | 82 (79–87) | 82 (74–88) | 0.601 |
NT-proBNP (ng/L) median (IQR) | 257 (194–432) | 253 (175–382) | 0.341 |
CHA2DS2-VASc, n median (IQR) | 3 (3–4) | 3 (3–4) | 0.734 |
CHA2DS2-VASc, n mean (95% CI) | 3.33 (2.93–3.74) | 3.36 (3.27–3.46) | 0.871 |
Congestive heart failure, n (%) | 2 (6) | 6 (1) | 0.113 |
Hypertension, n (%) | 18 (55) | 211 (51) | 0.722 |
Age (years) median (IQR) | 76.1 (75.8–76.6) | 76.4 (76.0–76.8) | 0.100 |
Diabetes Mellitus, n (%) | 3 (9) | 38 (9) | 1 |
Stroke/TIA, n (%) | 2 (6) | 31 (8) | 1 |
Vascular disease, n (%) | 2 (6) | 28 (7) | 1 |
Women, n (%) | 15 (45) | 232 (56) | 0.276 |
Palpitations before study entry, n (%) | 16 (48) | 135 (33) | 0.086 |
SVEBs per 30 s intermittent ECG, n median (IQR) | 0.89 (0.47–1.86) | 0.15 (0.04–0.72) | < 0.001 |
Number of intermittent recordings, n median (IQR) | 53 (50–58) | 53 (46–56) | 0.091 |
Micro-AFa, n (%) | 26 (79) | 170 (41) | < 0.001 |
Micro-AF episodes, n median (IQR) | 1 (1–2) | 0 (0–1) | < 0.001 |
Micro-AF episodes per 30 s intermittent recording, n median (IQR) | 0.02 (0.01–0.03) | 0 (0–0.02) | < 0.001 |
Longest Micro-AF episode (n of complexes) median (IQR) | 6 (5–8) | 0 (0–6) | < 0.001 |
Analysed signal time for continuous event recording (days) median (IQR) | 13.2 (12.4–13.5) | 12.4 (10.8–13.4) | 0.013 |